BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh A, Dhaliwal AS, Singh S, Kumar A, Lopez R, Gupta M, Noureddin M, Carey W, Mccullough A, Alkhouri N. Awareness of Nonalcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort. Dig Dis Sci 2020;65:978-86. [DOI: 10.1007/s10620-019-05700-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Alqahtani SA, Paik JM, Biswas R, Arshad T, Henry L, Younossi ZM. Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. Hepatol Commun. [DOI: 10.1002/hep4.1765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71:1851-1864. [PMID: 32012320 DOI: 10.1002/hep.31150] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 46.0] [Reference Citation Analysis]
3 Boutari C, Polyzos SA, Mantzoros CS. Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward. Metabolism 2021;122:154781. [PMID: 33901501 DOI: 10.1016/j.metabol.2021.154781] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Ciardullo S, Monti T, Perseghin G. Lack of awareness of liver organ damage in patients with type 2 diabetes. Acta Diabetol 2021;58:651-5. [PMID: 33496855 DOI: 10.1007/s00592-021-01677-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Shiha G, Korenjak M, Eskridge W, Casanovas T, Velez-Moller P, Högström S, Richardson B, Munoz C, Sigurðardóttir S, Coulibaly A, Milan M, Bautista F, Leung NWY, Mooney V, Obekpa S, Bech E, Polavarapu N, Hamed AE, Radiani T, Purwanto E, Bright B, Ali M, Dovia CK, McColaugh L, Koulla Y, Dufour JF, Soliman R, Eslam M. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol 2021;6:73-9. [PMID: 33031758 DOI: 10.1016/S2468-1253(20)30294-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 18.5] [Reference Citation Analysis]
6 Eslam M, Ahmed A, Després JP, Jha V, Halford JCG, Wei Chieh JT, Harris DCH, Nangaku M, Colagiuri S, Targher G, Joshi S, Byrne CD, Khunti K, Nguyen MH, Gish RG, George J. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol 2021;6:743-53. [PMID: 34265276 DOI: 10.1016/S2468-1253(21)00132-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Boursier J, Tsochatzis EA. Case-finding strategies in non-alcoholic fatty liver disease. JHEP Rep 2021;3:100219. [PMID: 33659890 DOI: 10.1016/j.jhepr.2020.100219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Expert Rev Gastroenterol Hepatol 2021;:1-14. [PMID: 34493137 DOI: 10.1080/17474124.2021.1974295] [Reference Citation Analysis]
9 Kang SH, Cho Y, Jeong SW, Kim SU, Lee JW; Korean NAFLD Study Group. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? Clin Mol Hepatol 2021;27:257-69. [PMID: 33751877 DOI: 10.3350/cmh.2021.0067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
10 Kim J, Lee M, Kim SY, Kim JH, Nam JS, Chun SW, Park SE, Kim KJ, Lee YH, Nam JY, Kang ES. Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts. Endocrinol Metab (Seoul) 2021;36:823-34. [PMID: 34474517 DOI: 10.3803/EnM.2021.1074] [Reference Citation Analysis]
11 Arab JP, Díaz LA, Dirchwolf M, Mark H, Lazarus JV, Vaughan E, Méndez-Sánchez N, de Oliveira CP, Gadano A, Arrese M. NAFLD: Challenges and opportunities to address the public health challenge in Latin America. Ann Hepatol 2021;24:100359. [PMID: 34004366 DOI: 10.1016/j.aohep.2021.100359] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Glass L, Asefa H, Volk M, Lok AS, Tincopa MA. Disease Knowledge, Health-Related Quality of Life, and Lifestyle Behavior Change in Patients with Nonalcoholic Fatty Liver Disease: Impact of an Educational Intervention. Dig Dis Sci 2021. [PMID: 34043121 DOI: 10.1007/s10620-021-07052-9] [Reference Citation Analysis]
13 Clayton M, Fabrellas N, Luo J, Alghamdi MG, Hafez A, Qadiri TA, Owise N, Attia D. From NAFLD to MAFLD: Nurse and allied health perspective. Liver Int 2021;41:683-91. [DOI: 10.1111/liv.14788] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
14 Le MH, Yeo YH, Cheung R, Wong VW, Nguyen MH. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016. J Intern Med 2020;287:711-22. [DOI: 10.1111/joim.13035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
15 Reimer KC, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int 2020;14:8-23. [PMID: 31802390 DOI: 10.1007/s12072-019-10001-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]